Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
STIMMALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 12:30 p.m. (ET) the same day. The presentation will be available via the conference portal to registered attendees.
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
STIMMALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.
Neuronetics Set To Join Russell 3000 Index And Russell 2000 Index, Effective June 30, 2025
STIMNeuronetics Sees Q2 Revenue Of $36M - $38M Vs. $36.690M Est.
STIMNeuronetics Q1 EPS $(0.21) Misses $(0.14) Estimate, Sales $31.98M Beat $29.07M Estimate
STIMNeuronetics Reports Updated Q4 Results; Net Loss $(0.33)
STIMCanaccord Genuity Maintains Buy on Neuronetics, Raises Price Target to $8
STIMCitizens Capital Markets Maintains Market Outperform on Neuronetics, Raises Price Target to $7
STIMNeuronetics Expects Q1 Revenue Of $28M-$30M Vs $21.02M Est, FY25 Revenue Of $145M-$155M Vs $93.55M Est
STIMNeuronetics Q4 2024 GAAP EPS $(0.33) Misses $(0.17) Estimate, Sales $22.493M Beat $19.634M Estimate
STIMNeuronetics Announces Q4 Revenue Of $22.1M And FY24 Revenue Of $74.5M; Projects 12%-19% Revenue Growth And $22M In Synergies For 2025; Aims For Cash Flow Breakeven In Q3 2025
STIMNeuroStar Advanced Therapy For Mental Health Announces Partnership With Mental Health Advocate And Former Major League Baseball Player Drew Robinson
STIMNeuronetics Earnings Conference Call Is Coming Up, Here's What You Need To Know
STIMNeuronetics (NASDAQ:STIM) will host a conference call at 08:30 AM ET on May 12, 2022, to discuss Q1 2022 earnings results.
How to Attend Neuronetics (STIM) Conference Call
Follow this link to access the live webcast.
